NHS Alliance calls for better recognition of clinical pharmacist role in ‘high street pharmacy’

NHS Alliance calls for better recognition of clinical pharmacist role in ‘high street pharmacy’

June 29 2016 The NHS should support clinical pharmacist roles in community pharmacies as well as...

Generics manufacturers call for retention of European registration system, post referendum

Generics manufacturers call for retention of European registration system, post referendum

June 29 2016 Generics medicines manufacturers are calling for Britain to keep the current...

Naloxone guidance updated to include supply to children young people

Naloxone guidance updated to include supply to children young people

June 27 2016 Guidance on naloxone supply has been updated with advice about what to consider when...

Pharmacy contractors say reform programme timetable is ‘unacceptably tight’

Pharmacy contractors say reform programme timetable is ‘unacceptably tight’

June 22 2016 The organisation representing pharmacy owner associations has criticised the lack of...

Consultation on how the Falsified Medicines Directive should be implemented

Consultation on how the Falsified Medicines Directive should be implemented

June 22 2016 A four week consultation has commenced asking how the European Falsified Medicines...

  • NHS Alliance calls for better recognition of clinical pharmacist role in ‘high street pharmacy’

    NHS Alliance calls for better recognition of clinical pharmacist role in ‘high street pharmacy’

    Wednesday, 29 June 2016 11:46
  • Generics manufacturers call for retention of European registration system, post referendum

    Generics manufacturers call for retention of European registration system, post referendum

    Wednesday, 29 June 2016 11:37
  • Naloxone guidance updated to include supply to children young people

    Naloxone guidance updated to include supply to children young people

    Tuesday, 28 June 2016 13:48
  • Pharmacy contractors say reform programme timetable is ‘unacceptably tight’

    Pharmacy contractors say reform programme timetable is ‘unacceptably tight’

    Wednesday, 22 June 2016 14:27
  • Consultation on how the Falsified Medicines Directive should be implemented

    Consultation on how the Falsified Medicines Directive should be implemented

    Wednesday, 22 June 2016 14:16

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

pills4June 27 2016

Guidance on naloxone supply has been updated with advice about what to consider when there is a need for use in people under 18 years.

The guidelines were introduced in October 2015 as part of a move to widen the availability of naloxone as an emergency antidote for overdoses caused by heroin and other opiates or opioids such as methadone and morphine.

They are intended for use by drug treatment services authorised to supply naloxone, including:

  • drug services commissioned from primary care providers
  • drug services commissioned from secondary care providers (including a range of specialised community and inpatient drug services)
  • commissioned services providing needle and syringe programmes (including those provided from pharmacies)
  • pharmacies providing drug treatment services.

The update says that “any drug treatment service considering providing a child or young person under 18 with training on overdose management or on the use of naloxone, or considering direct supply of naloxone, should always act in line with established clinical principles for the treatment of children and young people.

“This is the case whether the goal of such consideration is to reduce risks to a young person who is using drugs or to reduce risk for others (such as an opioid-using parent).”

It points out that there are no legal restrictions under the 2015 legislation, and that “such a decision would need very careful consideration and oversight and would need to be made on a case by case basis.

“An appropriately competent professional acting within a suitable clinical governance framework would have to consider the needs of each child or young person, taking account of potential benefits to the child of the intervention and any risks.”

Factors they would need to take into account include the child or young person’s ability to understand the issues involved and to provide suitable consent. “In the case of a child who exercises a carer role for a drug-using parent, consideration of the interests of the child can be quite complex.” There is also a need to consider issues such as those relating to child safeguarding.

Links:

Department of Health Guidance

Updated guidance

Legal & Policy News

June 29 2016 The NHS should support clinical pharmacist roles in community pharmacies as well as at GP practices, the New NHS Alliance has proposed.
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...